Abraham Chachoua, MD

Abraham Chachoua, MD, associate professor of Oncology, NYU Langone Medical Center, talks about the present use of anti-PD-1 and anti-PD-L1 treatments becoming the standard second-line treatment in lung cancer. He says that the treatments could become frontline treatments in the future, as single agents or in combination with other treatments, which is something researchers are currently working on.

Chachoua says one treatment in particular, nivolumab, was approved for squamous carcinoma and non-squamous carcinoma based on the CHECKMATE-057 trial. He adds that treatments like pembrolizumab were approved as well, though for patients that have PD-1 expression of greater than 50%. Chachoua said deciding who to test for PD-1 expression and who to give these treatments to is entirely up to the discretion of oncologists based on each individual patient.

Videos

Abraham Chachoua, MD, associate professor of Oncology, NYU Langone Medical Center, talks about the present use of anti-PD-1 and anti-PD-L1 becoming the standard second-line treatment in lung cancer.

Dr. Abraham Chachoua on Anti-PD-1 and Anti-PD-L1 Treatments in Lung Cancer

Abraham Chachoua, MD, director, Thoracic Oncology Research Program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, discusses some challenges of treating patients with lung cancer.

Learn about early detection and molecular testing in NSCLC > >

Articles

Abraham Chachoua, MD, discusses some challenges of treating patients with lung cancer.


Abraham Chachoua, MD | Authors

Articles

Dr. Abraham Chachoua on Anti-PD-1 and Anti-PD-L1 Treatments in Lung Cancer

The Challenges of Treating Lung Cancer